Photo caption: MD of BHTPA Hosne Ara Begum ndc and MD of Summit Technopolis Abu Reza Khan jointly handed over the 25 acres commercial plot to Kazi Shakil, Chairman of Oryx Biotech for setting up plasma fractionation plant at Bangabandhu Hi-Tech City, Gazipur.
(Dhaka) 14th February 2021, Sunday: Summit Technopolis, a subsidiary of Summit Group, within six months after tripartite agreement signing, handed over the possession of 25 acres of land to Oryx Bio-tech for setting up plasma fractionation plant. Prior to handing over, Summit Technopolis has completed extensive land improvement with additional BDT 5.14 Crore investment to meet the critical requirements for the development of the country’s first biotechnology plant. This biotech investment in Bangladesh with a valuation of USD 300 million will be built at the Block II of Bangabandhu Hi-Tech City, Gazipur.
Oryx Bio-tech is a subsidiary of Oryx Biotech Holdings based in China and it is expected that about 2,000 high-value science graduates will be employed when the plant is expected to commence operation in 2023 , subject to obtaining all the regulatory permissions.
Director of BHTPA A.N.M Shafiqul Islam, Deputy Director of BHTPA Md. Mahfuzul Kabir and other senior officials were also present at the handover ceremony at the ICT Tower in Agargaon.
About Summit Technopolis:
Summit Technopolis Limited, a Public Private Partnership (PPP), is the concessionaire for developing infrastructure for hi-tech industry comprising of Information Technology (IT), Information Technology Enabled Services (ITeS), bio-tech, non-polluting manufacturing assembly lines and precision engineering companies, in the 91 acres area in Bangabandhu Hi- Tech City, Kaliakoir, Gazipur. Summit Technopolis leased under the provision to design, build, finance, own, operate and transfer to the government on completion of 60 years lease period. For further information, you may visit: www.summittechnopolis.com
About Oryx Biotech Holdings:
Oryx Biotech Holdings, parent company of Oryx Bio-Tech Ltd., is a China-based biological product developer. With support of our partner, the NASDAQ USA-listed company namely China Biologic Products Holdings, Inc., which is the most technologically advanced and one of the largest Life Saving Therapeutics manufacturers in China. www.oryxbiotech.com
For further enquiries:
Mohsena Hassan | E: firstname.lastname@example.org | M: +88 0171 308 1905